Evidence map›Paper›PMID 42129147›Full record

ArticleTranslational psychiatry2026

Thalamic nuclei volumes across psychiatric and neurological disorders: a multi-site magnetic resonance imaging study.

V Mäki-Marttunen, S Nerland, K N Jørgensen, E A Høgestøl, J Rokicki, D Alnæs, S Borgwardt, B Boye, J Buitelaar, E Bøen and 26 more

Abstract readMulticenter Study
In one paragraph

Article in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Volumetric analysis of thalamic nuclei in children with vasovagal syncope.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

V Mäki-MarttunenCentre for Precision Psychiatry, Institute of Clinical Medicine, University of Oslo & Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway. makimarttunen.veronica@gmail.com.ORCID http://orcid.org/0000-0002-8527-091X
S NerlandCentre for Precision Psychiatry, Institute of Clinical Medicine, University of Oslo & Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
K N JørgensenCentre for Precision Psychiatry, Institute of Clinical Medicine, University of Oslo & Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0002-5751-4809
E A HøgestølDepartment of Neurology, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0001-8446-2111
J RokickiCentre for Research and Education in Forensic Psychiatry (SIFER), Oslo University Hospital, Oslo, Norway.
D AlnæsCentre for Precision Psychiatry, Institute of Clinical Medicine, University of Oslo & Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0001-7361-5418
S BorgwardtDepartment of Psychiatry and Psychotherapy, Department of Psychosomatics and Psychotherapy, Centre of Integrative Psychiatry, Schleswig-Holstein University Hospital, Campus Lübeck, Lübeck, Germany.
B BoyePsychosomatic and CL Psychiatry, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
J BuitelaarDepartment of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
E BøenPsychosomatic and CL Psychiatry, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0002-9546-2763
S CervenkaCentre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, Stockholm Region, Stockholm, Sweden.
A ConzelmannDepartment of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Psychiatry and Psychotherapy, Tübingen, Germany.
S ErhardtDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-7359-5250
B FrankeDepartments of Human Genetics and Psychiatry, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0003-4375-6572
E G CeliusDepartment of Neurology, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0002-9127-6488
H F HarboDepartment of Neurology, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.
E HillandFaculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.
P HoekstraDepartment of Child and Adolescent Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0003-1018-9954
C A HartmanInterdisciplinary Center Psychopathology and Emotion regulation (ICPE), Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0002-8094-8859
R JonassenFaculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.
E G JönssonCentre for Precision Psychiatry, Institute of Clinical Medicine, University of Oslo & Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
N I LandrøDepartment of Psychology, University of Oslo, Oslo, Norway.
K-P LeschDivision of Molecular Psychiatry, Center of Mental Health, University of Würzburg, Würzburg, Germany.ORCID http://orcid.org/0000-0001-8348-153X
L A MaglanocData Management, IT Department, University of Oslo, Oslo, Norway.
P PauliDepartment of Psychology I and Centre of Mental Health, University of Würzburg, Würzburg, Germany.ORCID http://orcid.org/0000-0003-0692-6720
C M SellgrenCentre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, Stockholm Region, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-9103-2785
G O NygaardDepartment of Neurology, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.
J OosterlaanEmma Children's Hospital, Amsterdam UMC location University of Amsterdam, Department of Pediatrics, Emma Children's Hospital Amsterdam UMC Follow-Me program & Emma Neuroscience Group, Meibergdreef 9, Amsterdam, The Netherlands.
A SchmidtDepartment of Clinical Research (DKF), University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0001-6055-8397
E SchwarzDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-0261-5063
G C ZieglerDivision of Molecular Psychiatry, Center of Mental Health, University of Würzburg, Würzburg, Germany.ORCID http://orcid.org/0000-0001-9411-3169
I AgartzCentre for Precision Psychiatry, Institute of Clinical Medicine, University of Oslo & Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
L T WestlyeCentre for Precision Psychiatry, Institute of Clinical Medicine, University of Oslo & Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0001-8644-956X
O A AndreassenCentre for Precision Psychiatry, Institute of Clinical Medicine, University of Oslo & Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0002-4461-3568
T KaufmannCentre for Precision Psychiatry, Institute of Clinical Medicine, University of Oslo & Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
T ElvsåshagenCentre for Precision Psychiatry, Institute of Clinical Medicine, University of Oslo & Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

Funding

EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 101086453EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 802998EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 847818Innovative Medicines Initiative (IMI) 115300Innovative Medicines Initiative (IMI) 777394Ministry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority) 2022043NordForsk 164218Norges Forskningsråd (Research Council of Norway) 324499, 324252, 344121
6 · The paper itself

Abstract

The human thalamus is an integrative hub for multiple cortical and subcortical circuits involved in sensory processing and higher cognitive functions. Thalamic volume differences have been reported across multiple psychiatric and neurological disorders, but previous studies have typically relied on small samples, focused on one or a limited number of disorders, or investigated the thalamus as a whole without considering its functional subdivisions. In this multi-site study, we compared thalamic nuclei volumes across mild cognitive impairment (MCI), dementia (DEM), major depressive disorder, schizophrenia spectrum disorder (SCZ), clinical high risk for schizophrenia, bipolar spectrum disorder, autism spectrum disorder, attention-deficit/hyperactivity disorder, Parkinson's disease, multiple sclerosis (MS), and healthy controls (N > 8000). Using structural MRI, we segmented 25 bilateral thalamic nuclei, corresponding to six anatomical groups. Linear models revealed that anterior, medial and lateral regions of the thalamus were significantly smaller in several conditions, with largest effects observed for MCI, DEM, SCZ and MS. In contrast, the ventral and intralaminar groups were relatively normal. This pattern of effects largely corresponds to the canonical functional subdivision of the thalamus into higher-order and sensory regions. At the level of individual nuclei, the clinical conditions were associated with distinct patterns of alterations, while left and right lateral geniculate nuclei were implicated in six of the disorders, suggesting a possible relation with circadian and sleep disturbances. Together, the results highlight a role for the higher-order thalamus in common brain disorders and a differential involvement at the nuclei level, refining our understanding of thalamic pathology across common brain disorders.

Indexed as

Mental DisordersNervous System DiseasesThalamic NucleiAgedFemaleHumansMagnetic Resonance ImagingMaleMiddle Agedmental disordersMRIneurological disorderssegmentationthalamus

Identifiers

PMID42129147
PMCPMC13338419

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.